Skip to main content

Table 3 Incidence and relative hazard of primary outcome by genotype

From: Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation

Gene

Genotype

No. Events (%)

Primary Outcome Incidence*

All Patients Adjusted HR (95%CI)† n = 628

P

Whites Adjusted HR (95%CI)† n = 524

P

Blacks Adjusted HR (95%CI)† n = 104

P

ADRB1

         

Ser49Gly

Ser/Ser

82 (18)

4.2

1.00 (reference)

 

1.00 (reference)

 

1.00 (reference)

 
 

Ser/Gly

30 (18)

3.8

0.88 (0.57–1.37)

0.58

0.89 (0.51–1.53)

0.66

1.12 (0.51–2.48)

0.78

 

Gly/Gly

3 (33)

6.4

1.02 (0.31–3.36)

0.98

...

0.98

1.95 (0.47–8.03)

0.36

Arg389Gly

Arg/Arg

44 (15)

3.2

1.00 (reference)

 

1.00 (reference)

 

1.00 (reference)

 
 

Arg/Gly

55 (20)

4.5

1.15 (0.77–1.71)

0.49

1.09 (0.69–1.72)

0.71

1.23 (0.56–2.83)

0.62

 

Gly/Gly

14 (26)

7.2

1.94 (1.05–3.59)

0.03

1.82 (0.92–3.61)

0.09

2.27 (0.53–9.79)

0.27

ADRB2

         

Gly16Arg

Gly/Gly

34 (18)

4.0

1.00 (reference)

 

1.00 (reference)

 

1.00 (reference)

 
 

Gly/Arg

57 (18)

4.0

0.93 (0.60–1.43)

0.73

0.90 (0.56–1.46)

0.67

1.09 (0.38–3.19)

0.87

 

Arg/Arg

24 (21)

4.6

1.14 (0.67–1.93)

0.63

0.81 (0.42–1.57)

0.53

2.61 (0.81–8.42)

0.11

Gln27Glu

Gln/Gln

52 (20)

4.4

1.00 (reference)

     
 

Gln/Glu

49 (17)

3.8

0.88 (0.59–1.30)

0.51

1.06 (0.67–1.71)

0.79

0.51 (0.20–1.30)

0.16

 

Glu/Glu

14 (18)

4.4

0.99 (0.53–1.84)

0.98

1.13 (0.59–2.15)

0.72

...

0.99

ADRB3 ‡

         

Trp64Arg

Trp/Trp

93 (18)

4.0

1.00 (reference)

 

1.00 (reference)

 

1.00 (reference)

 
 

Trp/Arg + Arg/Arg

21 (20)

4.8

1.32 (0.81–2.14)

0.26

1.19 (0.67–2.14)

0.55

1.33 (0.51–3.50)

0.56

ADRA1A

         

Arg347Cys

Arg/Arg

31 (18)

4.1

1.00 (reference)

 

1.00 (reference)

 

1.00 (reference)

 
 

Arg/Cys

58 (19)

4.4

1.03 (0.66–1.62)

0.88

0.97 (0.60–1.57)

0.89

1.05 (0.20–5.43)

0.95

 

Cys/Cys

26 (18)

3.5

0.68 (0.37–1.18)

0.16

0.83 (0.43–1.58)

0.56

0.46 (0.08–2.39)

0.35

GNAS

         

393 T > C

T/T

36 (18)

3.9

1.00 (reference)

 

1.00 (reference)

 

1.00 (reference)

 
 

T/C

58 (20)

4.5

1.10 (0.71–1.69)

0.67

1.26 (0.73–2.17)

0.40

0.97 (0.39–1.93)

0.74

 

C/C

21 (16)

3.6

1.31 (0.74–2.31)

0.36

1.60 (0.85–3.01)

0.15

...

0.99

GNB3

         

825 C > T

C/C

47 (16)

3.7

1.00 (reference)

 

1.00 (reference)

 

1.00 (reference)

 
 

C/T

42 (18)

3.8

1.06 (0.69–1.64)

0.78

1.26 (0.73–2.17)

0.40

0.87 (0.40–1.93)

0.74

 

T/T

26 (26)

6.1

1.51 (0.82–2.77)

0.19

1.60 (0.85–3.01)

0.15

...

0.99

  1. Abbreviations: HR, hazard ratio; 95%CI, 95% confidence interval
  2. * incidence per 100 patient-years
  3. † adjusted for age, race, presence of obstructive CAD, history of diabetes, ever-smoking, baseline systolic BP, BMI
  4. ‡ analyzed using dominant model based on minor allele frequency ≤ 0.1
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us